Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Vildé

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Presse Medicale (Paris, France : 1983)|May 16, 1992
[Non-typhic Salmonella bacteremias in HIV infections. Clinical and therapeutic data, and course in 68 patients]D Salmon-Ceron, P Detruchis, A Jaccard, et al.
Controlled Clinical Trials|June 10, 1998
Intention-to-treat vs. on-treatment analyses of clinical trial data: experience from a study of pyrimethamine in the primary prophylaxis of toxoplasmosis in HIV-infected patients. ANRS 005/ACTG 154 Trial GroupG Chêne, P Morlat, C Leport, et al.
The Journal of Infectious Diseases|January 1, 1996
Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Trial GroupC Leport, G Chêne, P Morlat, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 1, 1997
Increased risk of toxoplasmic encephalitis in human immunodeficiency virus-infected patients with pyrimethamine-related rash. ANRS 005-ACTG 154 Trial Group. Agence Nationale de Recherche sur le SIDA (ANRS-INSERM) and the NIAID-AIDS Clinical Trials GroupF Rousseau, S Pueyo, P Morlat, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 11, 2001
Salivary cytomegalovirus (CMV) shedding, glycoprotein B genotype distribution, and CMV disease in human immunodeficiency virus-seropositive patientsN Fidouh-Houhou, X Duval, F Bissuel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 29, 2000
Effect of a 14-day course of foscarnet on cytomegalovirus (CMV) blood markers in a randomized study of human immunodeficiency virus-infected patients with persistent CMV viremia. Agence National de Recherche du SIDA 023 Study GroupD Salmon-Céron, A M Fillet, J P Aboulker, et al.
AIDS (London, England)|November 1, 1996
Predictive value of Toxoplasma gondii antibody titres on the occurrence of toxoplasmic encephalitis in HIV-infected patients. ANRS 005/ACTG 154 Trial GroupF Derouin, C Leport, S Pueyo, et al.
Sante (Montrouge, France)|March 1, 1997
[Primary chemoprevention of tuberculosis in HIV-infected patients in non-industrialized countries]X Anglaret, F Dabis, J Batungwanayo, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|March 1, 1991
Treatment of acute toxoplasmosis with intravenous clindamycin. The California Collaborative Treatment GroupB R Dannemann, J A McCutchan, D M Israelski, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|April 15, 1997
Survival after AIDS-defining events in patients with < 200 lymphocytes CD4+ x 10(6)/L who are toxoplasmosis antibody positive. ANRS 005/ACTG 154 Trial GroupS Pueyo, L R Salmi, G Chêne, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Presse Medicale (Paris, France : 1983)|May 16, 1992
[Non-typhic Salmonella bacteremias in HIV infections. Clinical and therapeutic data, and course in 68 patients]D Salmon-Ceron, P Detruchis, A Jaccard, et al.
Controlled Clinical Trials|June 10, 1998
Intention-to-treat vs. on-treatment analyses of clinical trial data: experience from a study of pyrimethamine in the primary prophylaxis of toxoplasmosis in HIV-infected patients. ANRS 005/ACTG 154 Trial GroupG Chêne, P Morlat, C Leport, et al.
The Journal of Infectious Diseases|January 1, 1996
Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Trial GroupC Leport, G Chêne, P Morlat, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 1, 1997
Increased risk of toxoplasmic encephalitis in human immunodeficiency virus-infected patients with pyrimethamine-related rash. ANRS 005-ACTG 154 Trial Group. Agence Nationale de Recherche sur le SIDA (ANRS-INSERM) and the NIAID-AIDS Clinical Trials GroupF Rousseau, S Pueyo, P Morlat, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 11, 2001
Salivary cytomegalovirus (CMV) shedding, glycoprotein B genotype distribution, and CMV disease in human immunodeficiency virus-seropositive patientsN Fidouh-Houhou, X Duval, F Bissuel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 29, 2000
Effect of a 14-day course of foscarnet on cytomegalovirus (CMV) blood markers in a randomized study of human immunodeficiency virus-infected patients with persistent CMV viremia. Agence National de Recherche du SIDA 023 Study GroupD Salmon-Céron, A M Fillet, J P Aboulker, et al.
AIDS (London, England)|November 1, 1996
Predictive value of Toxoplasma gondii antibody titres on the occurrence of toxoplasmic encephalitis in HIV-infected patients. ANRS 005/ACTG 154 Trial GroupF Derouin, C Leport, S Pueyo, et al.
Sante (Montrouge, France)|March 1, 1997
[Primary chemoprevention of tuberculosis in HIV-infected patients in non-industrialized countries]X Anglaret, F Dabis, J Batungwanayo, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|March 1, 1991
Treatment of acute toxoplasmosis with intravenous clindamycin. The California Collaborative Treatment GroupB R Dannemann, J A McCutchan, D M Israelski, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|April 15, 1997
Survival after AIDS-defining events in patients with < 200 lymphocytes CD4+ x 10(6)/L who are toxoplasmosis antibody positive. ANRS 005/ACTG 154 Trial GroupS Pueyo, L R Salmi, G Chêne, et al.
Pageof 8